VIVUS — J.P. Morgan Healthcare Conference 2013
23 slides from VIVUS's conference presentation, Jan 7, 2013

Slide 1: J.P. Morgan Healthcare Conference 2013: Innovative Therapies, Novel Products
J.P. Morgan Healthcare Conference 2013 January 7-9, 2013 - San Francisco, California INNOVATIVE THERAPIES NOVEL PRODUCTS ©2013 VIVUS Inc. All rights reserved | www.vivus.com

Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect,"

Slide 3: Innovative Therapies; Novel Products
INNOVATIVE THERAPIES; NOVEL PRODUCTS Two newly approved products in high potential markets: Qsymia™ for chronic weight management Stendra™ for erectile dysfunction ©2013 VIVUS Inc. All rights reserved | www.vivus.com 2

Slide 4: Qsymia Prescribing Information
QSYMIA PRESCRIBING INFORMATION ©2013 VIVUS Inc. All rights reserved | www.vivus.com 3

Slide 5: Transforming the Obesity Market
TRANSFORMING THE OBESITY MARKET 4 ©2013 VIVUS Inc. All rights reserved | www.vivus.com 4

Slide 6: Building the Qsymia Franchise
Educate Physicians Broaden Reimbursement Expand to Retail Pharmacies Expand PCP Reach & DTC BUILDING THE QSYMIA FRANCHISE ©2013 VIVUS Inc. All rights reserved | www.vivus.com 5 Launch Time

Slide 7: Qsymia Prescriptions Launch to Date
QSYMIA PRESCRIPTIONS LAUNCH* TO DATE ©2013 VIVUS Inc. All rights reserved | www.vivus.com 6 Rolling Four Week TRx’s (000s) 0 2 4 6 8 10 12 14 0.6 5.4 7.7 13.0 3Q2012 10/26** 11/23 12/21 * Mid-Sep-2012; ** Adjusted Source: Vivus Data Warehouse - 21-Dec-2012 | Reported from 3rd parties and may be subj

Slide 8: Qsymia Cumulative Total Patients
QSYMIA CUMULATIVE TOTAL PATIENTS ©2013 VIVUS Inc. All rights reserved | www.vivus.com 7 Cumulative Patients (000s) 0 2 4 6 8 10 12 14 16 9/21 9/28 10/5 10/12 10/19 10/26 11/02 11/09 11/16 11/23 11/30 12/7 12/14 12/21 14.5 Source: Vivus Data Warehouse - 21-Dec-2012 | Reported from 3rd parties and may

Slide 9: Major PBM Validates Qsymia
MAJOR PBM VALIDATES QSYMIA Qsymia now on ESI National Preferred Formulary Among the largest Pharmacy Benefit Managers (PBM) Manages pharmacy benefit for 26.3MM lives U.S.* Tier 3; Prior Authorization Co-pay: ~$50 - $60 ©2013 VIVUS Inc. All rights reserved | www.vivus.com 8 *HealthLeaders InterStudy

Slide 10: Adult Obesity - A Costly Epidemic
1 Gonzalez, et al. NEJM 2010; 363:2211-9. 2 Flegal KM, et al. JAMA 2007;298:2028-2037 3 Logue, et al., Heart 2011:doi:10.1136/hrt 2010.211201 4 CDC National Center for Health Statistics. Health, United States, 2011 5 OECD Health at a Glance, December 2010, WHO The Challenge of Obesity in the WHO Eur

Slide 11: Qsymia Magnitude of Effect
©2013 VIVUS Inc. All rights reserved | www.vivus.com QSYMIA MAGNITUDE OF EFFECT PIVOTAL 1-YEAR STUDIES: WEIGHT LOSS OVER TIME (OBSERVED DATA) 10 Study 1 (EQUIP) Study 2 (CONQUER) Time (Week) Time (Week) 56 ITT-LOCF 56 ITT-LOCF All observed data; *p<0.0001 vs placebo; ‡p<0.0001 vs. Qsymia Mid or Low

Slide 12: Qsymia Consistency of Effect
QSYMIA CONSISTENCY OF EFFECT ©2013 VIVUS Inc. All rights reserved | www.vivus.com 11 *Dvorak, R., Peterson, C., Day, W. Application of Proposed Treatment Algorithm (PTA) Improves the Benefit/Risk Profile of Phentermine Plus Extended-Release Topiramate (PHEN/TPM ER) Presented at The Obesity Society 3

Slide 13: Building the Qsymia Franchise
Educate Physicians Broaden Reimbursement Expand to Retail Pharmacies Expand PCP Reach & DTC BUILDING THE QSYMIA FRANCHISE ©2013 VIVUS Inc. All rights reserved | www.vivus.com 12 Launch Time

Slide 14: Qsymia Tactical Accomplishments
QSYMIA TACTICAL ACCOMPLISHMENTS 13 Educate Prescribers Stimulate Patient Trial Improve Coverage of Obesity Expand to Retail Pharmacies Patient Awareness CME attendees: ~6,600 Details since launch: ~50,000 Qsymia Get Started! Program (14 Days Free) Express Scripts (ESI) adds Qsymia as Standard Pharma

Slide 15: Qsymia: Expansion to Retail
QSYMIA: EXPANSION TO RETAIL REMS Modification Submission to FDA: “...we request that you submit a REMS modification that will facilitate dispensing through a broader range of pharmacies...” (NDA Approval Letter) Submitted Oct-2012; six-month review expected GOAL: Expand from mail order-only to inclu

Slide 16: Qsymia Certified Pharmacies
Qsymia Home Delivery Network ©2013 VIVUS Inc. All rights reserved | www.vivus.com 15 Walmart Pharmacy QSYMIA CERTIFIED PHARMACIES Kaiser Permanente (For Kaiser members only)

Slide 17: Expanding the Qsymia Prescriber Base
EXPANDING THE QSYMIA PRESCRIBER BASE ©2013 VIVUS Inc. All rights reserved | www.vivus.com 16 Source: Vivus Data Warehouse - 21-Dec-2012 | Reported from 3rd parties and may be subject to adjustment

Slide 18: Qsymia Prescribers by Specialty
QSYMIA PRESCRIBERS BY SPECIALTY ©2013 VIVUS Inc. All rights reserved | www.vivus.com 17 Cumulative Unique Prescribers (000s) 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 9/21 9/28 10/5 10/12 10/19 10/26 11/02 11/09 11/16 11/23 11/30 12/7 12/14 12/21 2012 Source: Vivus Data Warehouse - 21-Dec-2012, All Pr

Slide 19: Qsymia: A Vision for the Brand
QSYMIA: A VISION FOR THE BRAND Obesity treatment becomes mainstream medicine Widely accepted by primary care physicians Broadly reimbursed Substantial consumer awareness & acceptance Qsymia will become the product of choice Double digit efficacy Well tolerated Improvements in co-morbidities ©2013 VI

Slide 20: Stendra Prescribing Information
STENDRA™ PRESCRIBING INFORMATION ©2013 VIVUS Inc. All rights reserved | www.vivus.com 19

Slide 21: Stendra
STENDRA™ Highly selective PDE5i with rapid onset EMA decision anticipated 1Q2013 Opportunity to commercialize in the US, EU and ROW Partnering discussions underway ©2013 VIVUS Inc. All rights reserved | www.vivus.com 20

Slide 22: VIVUS Investment Highlights
VIVUS INVESTMENT HIGHLIGHTS Two FDA approved products Making significant progress in building the Qsymia brand Educating physicians Expanding reimbursement Working to expand distribution Growing Qsymia prescriptions ©2013 VIVUS Inc. All rights reserved | www.vivus.com 21

Slide 23: Innovative Therapies Novel Products
INNOVATIVE THERAPIES NOVEL PRODUCTS ©2013 VIVUS Inc. All rights reserved | www.vivus.com
Source: SEC EDGAR · 8-K filed Jan 7, 2013
More decks from VIVUS Inc
Investor Presentation (September 2019)25 slides · Sep 5, 2019
Investor Presentation (January 2019)24 slides · Jan 7, 2019
Investor Presentation (November 2018)20 slides · Nov 27, 2018
Investor Presentation (January 2017)37 slides · Jan 10, 2017
Investor Presentation (January 2015)33 slides · Jan 15, 2015
Investor Presentation (June 2014)31 slides · Jun 17, 2014